Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07784283 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT07784283 · ClinicalTrials.gov record · last posted 2026-08-25

Integrating HPV Education Into School Health Programs in Cambodia and Kenya

StatusCompleted
PhaseNot applicable
Started2024-12-01
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The Clinton Health Access Initiative conducted a mixed-methods, school-based interventional study in Cambodia and Kenya to evaluate whether integrating age-appropriate human papillomavirus (HPV) education into existing school health education improves HPV vaccination coverage and students' knowledge and awareness of HPV, HPV vaccination, and cervical cancer. The study also assessed HPV vaccine-related attitudes and the feasibility, acceptability, and cost of the integrated education model. Schools were assigned to intervention or control using setting-specific procedures that combined geographic structuring and random elements rather than uniform school-level randomization. Intervention schools received integrated HPV education, while control schools continued existing curricula without the study-added package. Routine HPV vaccination eligibility, products, schedules, supply, and delivery arrangements were unchanged. Quantitative outcomes were assessed at baseline and endline using school immunization records and repeated cross-sectional student knowledge, attitudes, and practices questionnaires. Qualitative interviews with caregivers, teachers, and healthcare workers examined HPV-related knowledge, vaccination perceptions, accessibility, and implementation feasibility and acceptability. A costing analysis estimated intervention cost per immunization administered. The study included 46 schools in Cambodia and 160 in Kenya.
Trial Details
NCT Number NCT07784283
Lead Sponsor Clinton Health Access Initiative Inc.
Collaborators: Gavi, The Vaccine Alliance, Bill and Melinda Gates Foundation
Conditions Human Papillomavirus Vaccination, Cervical Cancer Prevention
Enrollment 9,054 participants
Start Date 2024-12-01
Primary Completion 2026-01-31 (estimated)
Study Completion 2026-01-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-25